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Abstract
Introduction: IFN-gamma inducible protein-10 (CXCL10), a member of the CXC chemokine family, and its receptor
CXCR3 contribute to the recruitment of T cells from the blood stream into the inflamed joints and have a crucial
role in perpetuating inflammation in rheumatoid arthritis (RA) synovial joints. Recently we showed the role of
CXCL10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in an animal model of RA and
suggested the contribution to osteoclastogenesis. We tested the effects of CXCL10 on the expression of RANKL in
RA synoviocytes and T cells, and we investigated which subunit of CXCR3 contributes to RANKL expression by
CXCL10.
Methods: Synoviocytes derived from RA patients were kept in culture for 24 hours in the presence or absence of
TNF-a. CXCL10 expression was measured by reverse transcriptase polymerase chain reaction (RT-PCR) of cultured
synoviocytes. Expression of RANKL was measured by RT-PCR and western blot in cultured synoviocytes with or
without CXCL10 and also measured in Jurkat/Hut 78 T cells and CD4+ T cells in the presence of CXCL10 or
dexamethasone. CXCL10 induced RANKL expression in Jurkat T cells was tested upon the pertussis toxin (PTX), an
inhibitor of Gi subunit of G protein coupled receptor (GPCR). The synthetic siRNA for Gai2 was used to knock
down gene expression of respective proteins.
Results: CXCL10 expression in RA synoviocytes was increased by TNF-a. CXCL10 slightly increased RANKL
expression in RA synoviocytes, but markedly increased RANKL expression in Jurkat/Hut 78 T cell or CD4+ T cell.
CXCL10 augmented the expression of RANKL by 62.6%, and PTX inhibited both basal level of RANKL (from 37.4 ±
16.0 to 18.9 ± 13.0%) and CXCL10-induced RANKL expression in Jurkat T cells (from 100% to 48.6 ± 27.3%). Knock
down of Gai2 by siRNA transfection, which suppressed the basal level of RANKL (from 61.8 ± 17.9% to 31.1 ±
15.9%) and CXCL10-induced RANKL expression (from 100% to 53.1 ± 27.1%) in Jurkat T cells, is consistent with PTX,
which inhibited RANKL expression.
Conclusions: CXCL10 increased RANKL expression in CD4+ T cells and it was mediated by Gai subunits of CXCR3.
These results indicate that CXCL10 may have a potential role in osteoclastogenesis of RA synovial tissue and
subsequent joint erosion.
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Interferon-gamma (IFN-g)-inducible protein 10 (CXCL10,
also called IP-10) was initially identified as a chemokine
that is induced by IFN-g and secreted by various cell types,
such as monocytes, neutrophils, endothelial cells, keratino-
cytes, fibroblasts, mesenchymal cells, dendritic cells, and
astrocytes [1]. CXCL10 is a 10-kDa protein and is func-
tionally categorized as an ‘inflammatory’ chemokine.
Moreover, CXCL10 lacking its ELR motif suppresses neo-
vascularization and functions as an ‘angiostatic’ chemokine
[2]. CXCL10 binds to CXCR3 and regulates immune
responses by activating and recruiting leukocytes, such as
T cells, eosinophils, monocytes, and natural killer cells
[3,4]. Three CXCR3-binding ligands are known, namely
CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (ITAC).
Recent reports have shown that the serum or tissue
expressions of CXCL10 or both are increased in various
autoimmune diseases like rheumatoid arthritis (RA), sys-
temic lupus erythematosus, systemic sclerosis, and multi-
ple sclerosis [5-8], and CXCL10 and CXCR3 may have
important roles in leukocytes homing to inflamed tissues
and in the perpetuation of inflammation and thus may
contribute importantly to tissue damage.
RA is a chronic inflammatory arthritis and is character-
ized by joint inflammation, synovial hyperplasia, and
excessive bone resorption, which are initiated by the
recruitment of activated T cells [9]. The regulation of
T-cell infiltration into synovium is an important aspect of
RA progression. Although it has been reported that many
chemokines and proinflammatory cytokines induce the
infiltration of inflammatory cells (mainly mononuclear
cells and T cells) into the synovium of inflamed joints and
thus mediate inflammation [10,11], the etiology of RA
remains unknown.
A Th1/Th2 cytokine imbalance with a predominance
of Th1 cytokines, including IFN-g, is suggested to be of
pathogenetic importance in RA [12-14]. The Th1 phe-
notype expresses certain chemokine receptors, including
CXCR3 and CCR5 [15,16].
CXCL10 has been detected in sera, synovial fluid, and
synovial tissue in patients with RA [5,17]. Furthermore,
its concentrations in RA synovial fluid have been
reported to be higher than in osteoarthritis (OA) syno-
vial fluid and higher than serum concentrations in
patients with RA [5]. CXCL10 is expressed mainly by
infiltrating macrophage-like cells and fibroblast-like
synoviocytes in RA synovium [5,18].
In our previous animal experiment, receptor activator
of nuclear factor-kappa B ligand (RANKL) induced
CXCL10 expression on osteoclast precursors, and, reci-
procally, CXCL10 upregulated RANKL expression in
CD4
+ T cells [18]. To examine the potential role of
CXCL10 in real osteoclastogenesis, osteoclast precursors
were cocultured with CD4
+ T cells in the presence of
CXCL10, and it was found that CXCL10 induced TRAP
(tartrate-resistant acid phosphatase)-positive osteoclast
differentiation in a dose-dependent manner. Further-
more, this differentiation induced by CXCL10 was sup-
pressed by osteoprotegerin (OPG) (a soluble RANKL
antagonist) and by neutralizing anti-CXCL10 antibody
[18]. The treatment of collagen-induced arthritis mice
with neutralizing anti-CXCL10 antibody not only sup-
pressed arthritis progression but also attenuated histolo-
gical bone loss [18]. Therefore, the purpose of this study
was to investigate the effects of CXCL10 on the expres-
sion of RANKL in human RA synoviocytes and CD4
+ T
cells and to find which subunit of CXCR3 contributes to
RANKL expression by CXCL10.
Materials and methods
Synovial fluid and sera
Synovial fluid and sera were collected from 18 patients
who had RA and who fulfilled the 1987 American College
of Rheumatology (ACR) criteria for RA and 11 patients
who had OA and who fulfilled ACR criteria for knee OA.
This study was approved by the institutional review
board of the Seoul National University College of Medi-
cine, and informed consent was obtained from all of the
sample donors in this study.
Reagent
Human CXCL10 was purchased from PeproTech (Rocky
Hill, NJ, USA) and TNF-a and interleukin-1-beta were
purchased from R&D Systems, Inc. (Minneapolis, MN,
USA). Pertussis toxin (PTX) was purchased from Cal-
biochem (now part of EMD Biosciences, Inc., San Diego,
CA, USA).
Cell culture
Synoviocytes were obtained from three patients who had
RA and who underwent total knee replacement arthro-
plasty. The synoviocytes were cultured for 24 hours in
the presence or absence of TNF-a (20 ng/mL). We used
two kinds of T-cell lines: Jurkat T cells and Hut 78 T
cells. These cells were cultured in the presence of
CXCL10 (10 or 100 ng/mL) or dexamethasone (10
-7 M).
CD4
+ T cells derived from healthy donors were isolated
from peripheral blood mononuclear cells by magnetic-
activated cell sorting (MACS) and cultured for 6 hours
in the presence of CXCL10 (100 ng/mL) or dexametha-
sone (10
-7 M).
Measurement of CXCL10
CXCL10 concentrations of synovial fluid and sera were
measured by a commercial enzyme-linked immunosor-
bent assay (ELISA) kit (R&D Systems, Inc.).
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CXCL10 expression in RA synoviocytes was measured by
reverse transcriptase-polymerase chain reaction (RT-PCR)
using primers (forward: TGACTCTAAGTGGCATT-
CAAGG; reverse: GATTCAGACATCTCTTCTCACCC)
and by Western blotting using anti-CXCL10 antibody
(R&D Systems, Inc.). RANKL expressions in synoviocytes,
Jurkat T cells, Hut 78 T cells, and CD4
+ T cells were mea-
sured by RT-PCR using primers (forward: GCCAGTGG-
GAGATGTTAG; reverse: TTAGCTGCAAGTTTTCCC),
by real-time polymerase chain reaction with Taqman
probe, and by Western blotting using anti-RANKL anti-
body purchased from R&D Systems, Inc. RANK expres-
sion in CD14
+ monocytes from healthy donors in the
presence of MCSF with or without CXCL10 was measured
by RT-PCR using primers (forward: TTAAGC-
CAGTGCTTCACGGG; reverse: ACGTAGACCACGAT-
GATGTCGC). Levels of OPG in cultured RA synoviocytes
were measured by using a commercial ELISA kit (R&D
Systems, Inc.).
RNA interference
The synthetic small interfering RNA (siRNA) for Gai2
and control (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) were used to knock down gene expression of
respective proteins. The siRNA transfection was per-
formed by electroporation using Gene Pulser II (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) at 250 V/950 F.
Immunoblot analysis
Cells were harvested and lysed in a lysis buffer (Cell Sig-
naling Technology, Inc., Danvers, MA, USA) by incubating
the suspension on ice for 20 minutes. The protein concen-
tration of the lysate was measured using the bicinchoninic
acid method. Fifty micrograms of the lysate protein was
boiled in a Lammli buffer, separated on a 10% SDS polya-
crylamide gel, and then transferred to a nitrocellulose
membrane. The blot was blocked with 5% non-fat milk for
1 hour and then incubated in a cold room overnight with
a specific antibody. The primary antibodies used were as
follows: antibody against RANKL; antibody against Gai2
from Santa Cruz Biotechnology, Inc.; antibody against
phosphorylated CREB (cAMP-response element binding)
(Ser133) from Cell Signaling Technology, Inc.; and actin
antibody from Sigma-Aldrich (St. Louis, MO, USA). The
nitrocellulose membrane was subsequently washed and
incubated with a peroxidase-labeled rabbit anti-goat IgG
antibody for 2 hours at room temperature and then incu-
bated with an enhanced chemiluminescence substrate
mixture (Pierce, Rockford, IL, USA). The blot was then
exposed on x-ray film (AGFA Curix RPI; Agfa HealthCare
N V ,M o r t s e l ,B e l g i u m )t oo b t a i na ni m a g e .D e n s i t i e so f
visualized bands were quantified using an image analyzer
(Model Multi Gauge V2.3; Fujifilm, Tokyo, Japan).
Results
CXCL10 concentrations were increased in patients with
RA and CXCL10 expressions in RA synoviocytes were
increased by TNF-a
We compared CXCL10 concentration of synovial fluids
and sera in 18 patients with RA and 11 patients with OA.
Demographic data of both sets of patients at the time of
sampling are presented in Table 1. As shown in Figure 1,
CXCL10 concentrations were significantly increased in
RA synovial fluid (mean ± standard error: 1,502.0 ± 87.1
pg/mL versus 267.3 ± 87.0 pg/mL; P < 0.01) and sera
(363.9 ± 78.9 pg/mL versus 87.7 ± 10.8 pg/mL; P <0 . 0 1 )
than in those of OA. Furthermore, the concentration of
CXCL10 in inflamed synovial fluid is much higher than
in sera of patients with RA (1,502.0 ± 87.1 pg/mL versus
363.9 ± 78.9 pg/mL; P < 0.05). Although the baseline
expression level of CXCL10 varied in individual patients,
CXCL10 expression in RA synoviocytes was increased by
TNF-a (Figure 2).
CXCL10 induced RANKL in CD4
+ T cells and synoviocytes
We found that CXCL10 could induce RANKL in RA syno-
viocytes but that RANKL expression induced by CXCL10
was relatively weak (Figure 3) and showed high individual
variation (Additional file 1). We also checked the effect of
CXCL10 on RANKL expression in T cells because acti-
vated T cells could express RANKL and contribute to
osteoclastogenesis in RA. As shown in Figure 4, CXCL10
increased RANKL expression in Jurkat T cells (A) and
Hut 78 T cells (B). Dexamethasone-induced RANKL
expression was potentiated by the addition of CXCL10.
We checked RANKL expression in primary CD4
+ T cells
from healthy donors in the presence or absence of
CXCL10 and found that CXCL10 independently could
induce RANKL in human CD4
+ T cells (Figure 5). We
Table 1 Demographic data of patients with osteoarthritis
and those with rheumatoid arthritis
Osteoarthritis
(n = 11)
Rheumatoid
arthritis
(n = 18)
Age in years, mean ± SD 67.20 ± 7.35 57.17 ± 9.51
Females/Males 10:1 17:1
Duration of disease in months,
mean ± SD
79.64 ± 62.66 114.85 ± 49.54
Treatment, number (percentage)
Prednisolone 15 (83%)
DMARDs 18 (100%)
Methotrexate 16 (89%)
Sulfasalazine 2 (11%)
Hydroxychloroguine 7 (39%)
Leflunomide 5 (28%)
Azathioprine 3 (17%)
DMARD, disease-modifying antirheumatic drug; SD, standard deviation.
Lee et al. Arthritis Research & Therapy 2011, 13:R104
http://arthritis-research.com/content/13/3/R104
Page 3 of 8searched the effect of CXCL10 on RANK expression on
CD14
+ monocytes and OPG level in RA synoviocytes
(Additional file 2). Finally, there was no significant effect
on RANK expression in monocytes after CXCL10 stimula-
tion. CXCL10 stimulation did not significantly induce or
reduce OPG production in cultured synoviocytes or Jurkat
Tc e l l s .
Gai subunits were involved in CXCL10-induced RANKL
expression in jurkat T cells
To investigate whether Gai subunits are involved in
CXCL10-induced RANKL expression, we used PTX, a
bacterial toxin that inhibits Gai activation by ADP-ribosy-
lating Gai subunits, and the inhibition of Gai by PTX was
confirmed by measuring CREB phosphorylation that was
increased following Gai inhibition. Figure 6 shows that
CXCL10 augmented the expression of RANKL more than
twofold and that PTX inhibited both basal level of
RANKL (from 37.4% ± 16.0% to 18.9% ± 13.0%) and
CXCL10-induced RANKL expression in Jurkat T cells
(from 100% to 48.6% ± 27.3%). Next, to prove the involve-
ment of Gai in regulating CXCL10-induced RANKL
expression, we analyzed the effect of Gai2 siRNA on
CXCL10-induced RANKL expression. Knockdown of Gai2
by siRNA transfection, which suppressed the basal level of
RANKL (from 61.8% ± 17.9% to 31.1% ± 15.9%) and
CXCL10-induced RANKL expression (from 100% to 53.1
± 27.1%) in Jurkat T cells, is consistent with PTX, which
Figure 1 Comparison of CXCL10 concentrations between patients with rheumatoid arthritis (RA) and those with osteoarthritis (OA).
CXCL10 concentrations of synovial fluid (a) and sera (b) were measured by enzyme-linked immunosorbent assay. CXCL10 concentrations were
significantly increased in synovial fluid and sera of RA in comparison with those of OA. Data were expressed as mean ± standard error. CXCL10,
interferon-gamma-inducible protein 10.
Figure 2 CXCL10 expressions in rheumatoid arthritis (RA)
synoviocytes (Western blot and reverse transcriptase-
polymerase chain reaction). Human RA synoviocytes were
cultured in the presence or absence of tumor necrosis factor-alpha
(TNF-a) for 24 hours. Without TNF-a stimulation, low expressions of
CXCL10 were observed in RA synoviocytes with high individual
variation. However, with TNF-a stimulation, CXCL10 expression in
RA synoviocytes was significantly increased. CXCL10, interferon-
gamma-inducible protein 10; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; RT-PCR, reverse transcriptase-polymerase chain
reaction.
Figure 3 Induction of receptor activator of nuclear factor
kappa-B ligand (RANKL) by CXCL10 in rheumatoid arthritis
(RA) synoviocytes (reverse transcriptase-polymerase chain
reaction). CXCL10 (10 ng/mL) induced RANKL in RA synoviocytes.
Tumor necrosis factor-alpha (TNF-a) (10 ng/mL) alone weakly
induced RANKL expression in this sample. However, when CXCL10
was added to TNF-a, RANKL expression increased. Interleukin-1-beta
(IL-1b) (10 ng/mL) alone induced RANKL gene expression, and band
intensity did not change when CXCL10 was added. CXCL10,
interferon-gamma-inducible protein 10; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
Lee et al. Arthritis Research & Therapy 2011, 13:R104
http://arthritis-research.com/content/13/3/R104
Page 4 of 8inhibited RANKL expression (Figure 7). These results indi-
cate that Gai subunits are involved in CXCL10-induced
RANKL expression in Jurkat T cells.
Discussion
The regulation of osteoclasts is vital for maintaining bal-
ance in bone remodeling. Bone resorbing osteoclasts are
derived from hemopoeitic cells of the monocyte/macro-
phage lineage and differentiate into multinucleated cells
through multiple processes [19]. Osteoclast formation and
activity are regulated by local factors and by stromal and
osteoblast cells in the bone environment [20]. Several che-
mokines promote bone resorption by inducing osteoclast
formation and survival and by directly inducing the migra-
tion and adhesion of leukocytes [21,22]. For example, the
expressions of macrophage inflammatory protein-1a
(MIP-1a,C C L 3 )a n dM I P - 1 b (CCL4) in multiple myeloma
cells were found to enhance osteolytic lesions by enhan-
cing osteoclast formation and bone resorption, and, more
recently, CCR2 was shown to increase expression of
RANK and enhance RANK signaling in ovariectomized
mice [23,24]. Of the several osteoclastogenic factors,
RANKL, which is expressed on stromal and osteoblast
cells, is known to play an essential role in osteoclast differ-
entiation and function. Furthermore, the regulation of
RANKL expression is known to be important for prevent-
ing bone disorders caused by increased osteoclast
formation.
In our experiments, CXCL10 increased RANKL expres-
sion in RA synoviocytes and directly increased RANKL
expression in Jurkat/Hut 78 T cells or human CD4
+ T
cells. These results are compatible with our previous ani-
mal experiments showing that CXCL10 upregulated
RANKL expression in mouse T cells and induced TRAP-
positive osteoclast differentiation [18]. In both human
and mouse systems, CXCL10 can induce RANKL expres-
sion, mainly in CD4
+ T cells, and then may contribute to
osteoclastogenesis.
CXCL10-induced RANKL expression in human T cells
seems to be mediated by Gai subunits of CXCR3, which is
a well-known receptor for CXCL9, CXCL10, and CXCL11.
CXCR3 is a G protein-coupled, seven-transmembrane
receptor and has heterotrimeric G proteins consisting of a,
b,a n dg subunits. The G protein resides attached to the
Figure 4 Induction of receptor activator of nuclear factor kappa-B ligand (RANKL) by CXCL10 in T-cell lines (Western blot).C X C L 1 0
increased RANKL protein expression in Jurkat T cells (a) and Hut 78 T cells (b). Dexamethasone was used as a positive control in this
experiment, and dexamethasone-induced RANKL expression was potentiated by the addition of CXCL10. CXCL10, interferon-gamma-inducible
protein 10.
Figure 5 Induction of receptor activator of nuclear factor kappa-B ligand (RANKL) by CXCL10 in CD4
+ T cells (Western blot).H u m a n
CD4
+ cells from healthy donors were used in this experiment, and CXCL10 increased RANKL protein expression in human primary CD4
+ T cells.
CXCL10, interferon-gamma-inducible protein 10.
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form consisting of the Ga subunit bound to GDP, a struc-
ture that is stabilized by interaction with the bg dimer.
Upon interaction with the receptor, Ga protein becomes
activated, causing GDP exchange for GTP. The GTP-bind-
ing proteins are classified by the signaling events they insti-
gate, of which there are four major families: Gai/o,G aq/11,
Ga12/13,a n dG as [25,26]. T lymphocytes usually express
Gai, which plays a major role in chemotaxis, proliferation,
and differentiation of various cells [27,28]. In our experi-
ment, depletion of Gai subunit by siRNA or PTX sup-
pressed the RANKL basal level and CXCL10-induced
RANKL expression in Jurkat T cells. These results suggest
that the Gai subunit of CXCR3 in T lymphocytes mediates
CXCL10-induced RANKL expression and may contribute
to osteoclastogenesis.
Our data showed that CXCL10 levels in sera and syno-
vial fluid in patients with RA were significantly higher
than those of patients with OA. CXCL10 expression in
RA synoviocytes is upregulated by TNF-a,w h i c hi sa
major pathologic cytokine in RA. The increased amount
of CXCL10 and TNF-a may recruit osteoclast precursor
cells, induce RANKL, and then induce osteoclastogenesis.
This kind of auto- or paracrine amplification loop may
contribute to chronic bone destructive damage in
inflamed RA joints.
Conclusions
CXCL10 increased RANKL expression in CD4
+ Tc e l l s
and was mediated by Gai subunits of CXCR3. In addi-
tion to having a role in the recruitment of proinflamma-
tory cells, CXCL10 may have a potential role in
Figure 6 Effect of pertussis toxin (PTX) on CXCL10-induced expression of receptor activator of nuclear factor kappa-B ligand (RANKL).
Expression was assessed by immunoblot assay (a) and densitometry (b). Jurkat T cells were pretreated with 200 ng/mL PTX for 18 hours and
then treated with 10 ng/mL CXCL10 for 6 hours. RANKL expression was assessed by immunoblot analysis using a specific antibody against
RANKL. The immonoblot assays shown are representative of at least four independent experiments, and the histograms show average and
standard deviations of representative RANKL expression. CXCL10, interferon-gamma-inducible protein 10.
Figure 7 Effect of Gai2 siRNA (small interfering RNA) on CXCL10-induced expression of receptor activator of nuclear factor kappa-B
ligand (RANKL). Jurkat T cells were transfected with Gai2 and control siRNA by electroporation. After 48 hours, the cells were treated with 10
ng/mL CXCL10 for 6 hours, and then RANKL expression was assessed by immunoblot analysis using a specific antibody against RANKL (a). The
bolts shown are representative of at least four independent experiments, and the histograms show average and standard deviations of
representative RANKL expression (b). CXCL10, interferon-gamma-inducible protein 10.
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joint erosion.
Additional material
Additional file 1: Receptor activator of nuclear factor kappa-B
ligand (RANKL) induction by CXCL10 in rheumatoid arthritis (RA)
synoviocytes and Jurkat T cell (real-time PCR). RANKL induction by
CXCL10 in RA synoviocytes (n = 3) showed high individual variation but
there was an increasing tendency of RANKL expression by CXCL10
stimulation. In Jurkat T cell, CXCL10 highly increased RANKL expression.
Additional file 2: Effect of CXCL10 on receptor activator of nuclear
factor kappa-B (RANK) expression in CD14
+ mococytes (reverse
transcriptase-polymerase chain reaction). CD14
+ mococytes derived
from healthy donor were isolated by MACS microbeads and cultured in
the presence of MCSF (25 ng/mL) with or without CXCL10 (10 ng/mL or
100 ng/mL). After 24 or 48 hour, the cells were collected and then RANK
expression was assessed by RT-PCR (A). Effect of CXCL10 on
osteoprotegerin (OPG) production in rheumatoid arthritis (RA)
synoviocytes (enzyme-linked immunosorbent assay). RA synoviocytes
(n = 3) were cultured in the presence or absence of CXCL10 (10 ng/mL
or 100 ng/mL) for 24 or 48 hours and then, culture media were collected
for measurement of OPG.
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